This EASL Studio Midday Talks was live broadcast during the EASL Congress 2023 and is presenting the work of international liver societies to beat liver diseases.

Faculty

• Thomas Berg, EASL (Moderator)
• Marcelo Silva, ALEH (Faculty)
• Norah Terrault, AASLD (Faculty)
• Manal El-Sayed, SOLDA (Faculty)
• Shiina Shuichiro, APASL (Faculty)

All EASL Studio Podcasts are available on EASL Campus.

This EASL Studio Closing was live broadcast during the EASL Congress 2023 and discusses the future of hepatology.

Faculty

• Thomas Berg (Moderator)
• Aleksander Krag (Moderator)
• Tobias Böttler (Faculty)
• Debbie Shawcross (Faculty)

All EASL Studio Podcasts are available on EASL Campus.

This EASL Studio Good Morning Vienna was live broadcast during the EASL Congress 2023 and is presenting the highlights of liver cancer research at the congress.

Faculty

• Jean-Charles Nault (Moderator)
• Josep Llovet (Moderator)
• Jessica Zucman-Rossi (Faculty)
• Bruno Sangro (Faculty)
• Matthias Pinter (Faculty)

All EASL Studio Podcasts are available on EASL Campus.

This EASL Studio Midday Talks was live broadcast during the EASL Congress 2023 and discusses the newly released EASL policy statement on alcohol harm and related liver diseases. The document aims to highlight the extensive harm resulting from alcohol consumption and shine a light on the effective, yet underused, harm reduction policies available to European countries.

Faculty

• Frank Murray Ireland (Moderator)
• Maria Buti (Moderator)
• Thomas Babor (Faculty)

All EASL Studio Podcasts are available on EASL Campus.

This EASL Studio Midday Talks was live broadcast during the EASL Congress 2023 and discusses the nomenclature change for steatotic liver disease.

Faculty

• Aleksander Krag, EASL (Moderator)
• Philip Newsome, EASL (Faculty)
• Maru Rinella, AASLD (Faculty)
• Graciela Castro-Narro, ALEH (Faculty)
• Mohamed El-Kassas, SOLDA (Faculty)
• Robert Mitchell-Thain, LPI (Faculty)
• Lorraine Stiehl, ALF (Faculty)

All EASL Studio Podcasts are available on EASL Campus.

This EASL Studio Midday Talks was live broadcast during the EASL Congress 2023 and is covering practice changing following data presented during the congress.

Faculty

• Virginia Hernández-Gea (Moderator)
• Ahmed Elsharkawy (Moderator)
• Maru Rinella (Faculty)
• Maria Reig (Faculty)
• Nancy Reau (Faculty)
• Verena Keitel (Faculty)

All EASL Studio Podcasts are available on EASL Campus.

In honour of International NASH Day, the final episode of EASL Studio season 4 is shedding light on non-alcoholic steatohepatitis (NASH), a disease with increasing global prevalence but low awareness.

Faculty

• Zobair Younossi (Moderator)
• Alina M. Allen (Faculty)
• Sven Francque (Faculty)
• Vincent Wong (Faculty)
• Shira Zelber-Sagi (Faculty)

All EASL Studio Podcasts are available on EASL Campus.

Non-alcoholic steatohepatitis (NASH) is rapidly emerging as a leading cause of chronic liver disease, presenting significant challenge due to the limited treatment options available.

This EASL Studio JHEP Live aims to explore novel and promising treatments currently being evaluated for the treatment of NASH. In particular:

• ARO-HSD, an HSD17β13 inhibitor.
• PXL065 under evaluation in the DESTINY-1 trial.
• The investigation of an FXR agonist in fibrotic NASH as part of the LIVIFY trial.

Faculty

• Prof. Vlad Ratziu (Moderator)
• Prof. Stephen Harrison (Faculty)
• Dr Rohit Loomba (Faculty)
• Dr Loey Lung-Yi Mak (Faculty)

Related articles

• A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis
• Evaluation of PXL065 – deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)
• Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH

All EASL Studio Podcasts are available on EASL Campus.

Clinical evidence indicates that cigarette smoking negatively impacts the incidence and severity of fatty liver disease, fibrosis progression, hepatocellular carcinoma development, and the outcomes of patients with advanced liver disease. The underlying mechanisms are complex and involve different pathophysiological pathways including oxidative stress and oncogenic signals.

To coincide with World No Tobacco Day, 31 May, this EASL Studio discusses some of the pathophysiological mechanisms that drive the progression of liver disease and cancer risk in those who smoke.

Faculty

• Prof. William Alazawi (Moderator)
• Prof. Debbie Shawcross (Moderator)
• Prof. Ramon Bataller (Faculty)
• Prof. Vanessa Stadlbauer-Köllner (Faculty)

All EASL Studio Podcasts are available on EASL Campus.

Collaborations are key in achieving scientific progress. The European Horizon COST Actions provide great opportunities to build, grant, and/or participate in pan-European collaborations in multidisciplinary topics, including liver diseases.

This EASL Studio:

• Provides you with information about the COST Action programme.
• Discusses the structure of the drug-induced liver injury (DILI) and cholangiocarcinoma (CCA) working groups.
• Highlights the potential for collaborative work within this programme.

Faculty

• Prof. Jesús Bañales (Moderator)
• Prof. Raul Andrade (Faculty)
• Dr Chiara Braconi (Faculty)
• Prof. Vincenzo Cardinale (Faculty)

Related episodes

• S4E13: EASL-EF CLIF and EU Grants: Exploring novel mechanisms and treatment of chronic liver failure
• S4E2: YI Choice: How to build consortia and registries

All EASL Studio Podcasts are available on EASL Campus.